Kaposi’s sarcoma: a 10-year experience with 248 patients at a single tertiary care hospital in Tanzania

BMC Research Notes

Samuel E. Kalluvya⁵  Martha F. Mushi³  Mariam Mirambo³  Nestory Masalu¹  Hyasinta Jaka⁵  Peter F. Rambau⁴  Fidelis Mbunda²  Phillipo L. Chalya² 

[1] Department of Oncology, Bugando Medical Centre, Mwanza, Tanzania;Department of Surgery, Bugando Medical Centre, Mwanza, Tanzania;Department of Microbiology, Catholic University of Health and Allied Science-Bugando, Mwanza, Tanzania;Department of Pathology, Catholic University of Health and Allied Science-Bugando, Mwanza, Tanzania;Department of Internal Medicine, Catholic University of Health and Allied Science-Bugando, Mwanza, Tanzania

关键词: Tanzania;    Treatment outcome;    Clinicopathological;    Acquired immunodeficiency syndrome;    Human immunodeficiency virus;    Kaposi’s sarcoma;   

Others  :  1230151
DOI  :  10.1186/s13104-015-1348-9

 received in 2014-11-12, accepted in 2015-08-17,  发布年份 2015

【 摘 要 】

Background

Kaposi’s Sarcoma is the most common sarcoma and second most prevalent cancer seen in Tanzania. Little is known about Kaposi’s sarcoma in our setting as there is paucity of recent published data regarding this condition. This study describes the clinicopathological pattern and treatment outcome of Kaposi’s sarcoma at Bugando Medical Centre, a tertiary care hospital in northwestern Tanzania.

Methods

This was a prospective study of histologically confirmed Kaposi’s sarcoma that was conducted at Bugando Medical Center between July 2004 and June 2014.

Results

A total of 248 patients (M:F = 1.4:1) representing 2.4 % of all malignancies during the study period were enrolled into the study. The median age at presentation was 36 years. Females were younger than males (p = 0.04). Out of 248 patients, 122 (49.2 %) were HIV positive. Of these, 46 (37.7 %) were males and 76 (62.3 %) females. AIDS-related Kaposi’s sarcoma were younger than HIV negative Kaposi’s sarcoma patients (p = 0.011). Median duration of symptoms was 6 months. Kaposi’s sarcoma was the AIDS defining disease in 82 (67.2 %) patients while in the remaining 40 (32.8 %) it was diagnosed between 1 and 14 months after the initial diagnosis of AIDS. The lower limb was most frequently involved site in 28.9 % of patient. Females had more disseminated lesions compared with more localized lesions in the males (p = 0.001). The treatment modalities in this study included chemotherapy, radiotherapy, surgery and highly active antiretroviral therapy. Overall 126 (53.4 %) patients had significant improvement in quality of life at the end of 1 year follow up. Treatment related complication and mortality rates were 25.8 and 24.2 % respectively. Poor ACTG stage, CD4+ count <200 cells/µl, associated co-morbid illness, disseminated disease and poor adherent to chemotherapy were the significant independent factors associated with deaths (p < 0.001). Patient’s follow-up was generally poor and data on long-term survivals were not available as more than two-thirds of patients were lost to follow up.

Conclusion

Kaposi’s sarcoma is the most common malignant vascular tumor and HIV/AIDS- related cancer in our region. There is an urgent need to develop health education programmes to enhance the understanding of this disease and how it spreads, particularly among the younger generation.

【 授权许可】

   
2015 Chalya et al.

【 参考文献 】

• [1]Kagu MB, Nggada HA, Garandawa HI, Askira BH, Durosinmi MA: AIDS-associated Kaposi’s sarcoma in Northeastern Nigeria. Singapore Med J 2006, 47:1069-1074.
• [2]Bisacchi D, Noonan DM, Carlone S, Albini A, Pfeffer U: Kaposi’s sarcoma and human chorionic gonadotropin: mechanisms, moieties and mysteries. Biol Chem 2002, 383:1315-1320.
• [3]Kaposi M: Idiopathic multiple pigmented lesions of the skin. Arch Dermatol Syph 1872, 4:265-273.
• [4]Stein ME, Spencer D, Ruff P, Lakier R, MacPhail P, Bezwoda WR: Endemic African Kaposi sarcoma: clinical and therapeutic implications, 10-year experience in Johannesburg Hospital (1980–1990). Oncology 1994, 51:63-69.
• [5]Sitas F, Pacella-Norman R, Carrara H, Patel M, Ruff P, Sur R, Jentsch U, Hale M, Rowji P, Saffer D, Connor M, Bull D, Newton R, Beral V: Spectrum of HIV-I related cancers in South Africa. Int J Cancer 2000, 88:489-492.
• [6]Friedman-Kien AE: Disseminated Kaposi’s sarcoma syndrome in young homosexual men. J Am Acad Dermatol 1981, 5:468-471.
• [7]Susan E: Therapy of AIDS-associated Kaposi’s sarcoma: targeting pathogenetic mechanisms. Hematol Oncol Clin N Am 2003, 17:763-783.
• [8]O’Donnell PJ, Pantanowitz L, Grayson W: Unique histologic variants of cutaneous Kaposi sarcoma. Am J Dermatopathol 2010, 32:244-250.
• [9]Patel RM, Goldblum JR, Hsi ED: Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcoma. Mod Pathol 2004, 17:456-460.
• [10]Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al.: Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 2006, 20:1645-1654.
• [11]Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, et al.: The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003: the Euro SIDA Study. Cancer 2004, 100:2644-2654.
• [12]Sasco AJ, Jaquet A, Boidin E, Ekouevi DK, Thouillot F, Lemabec T, et al.: The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One 2010, 5:e8621.
• [13]Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S: Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer 2000, 82:1585-1592.
• [14]Bassett MT, Chokunonga E, Mauchaza B, Levy L, Ferlay J, Parkin DM: Cancer in the African population of Harare, Zimbabwe, 1990–1992. Int J Cancer 1995, 63:29-36.
• [15]Ahmed A, Muktar HM, Bugaje MA: Epidemiological and clinical features of AIDS-Associated Kaposi’s sarcoma in Northern Nigeria. Arch Int Surg 2013, 3:29-34.
• [16]Mandong BM, Chirdan LB, Anyebe AO, Mannaseh AN: Histopathological study of Kaposi’s sarcoma in Jos: a 16 year review. Ann Afr Med 2004, 3:174-176.
• [17]Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994, 266:1865-1869.
• [18]Slavin G, Cameron HM: Kaposi’s sarcoma in East African children. J Pathol 1970, 100:187-199.
• [19]Kyalwazi SIC: Histological classification of Kaposi’s sarcoma: a basis for chemotherapy. East Afr Med J 1976, 53:670-676.
• [20]Agaba PA, Sule HM, Ojohoh RO, Hassan Z, Apena L, Muazu MA, Badung , Agbaji OO, Idoko JA, Kanki P: Presentation and survival of patients with AIDS-related Kaposi’s sarcoma in Jos, Nigeria. Int J STD AIDS 2009, 20:410-413.
• [21]Amir H, Kaaya EE, Manji KP, Kwesigabo G, Biberfeld P: Kaposi’s sarcoma before and during a human immunodeficiency virus epidemic in Tanzanian children. Pediatr Infect Dis J 2001, 20:518-521.
• [22]Urassa WK, Kaaya EE, Kitinya JN, Lema LEK, Amir H, Luande J, Biberfeld G, Mhalu FS, Biberfeld P: Immunological profile of endemic and epidemic Kaposi’s sarcoma patients in Dar-es Salaam, Tanzania. Int J Mol Med 1998, 1:979-982.
• [23]Mwakigonja AR, Pak F, Pyakurel P, Mosha IJ, Urassa WK, Kaaya EE, Biberfeld P: Oral Kaposi’s sarcoma in Tanzania: presentation, immunopathology and human herpesvirus-8 association. Oncol Rep 2007, 17:1291-1299.
• [24]Lyamuya EF, Aboud S, Urassa WK, Sufi J, Mbwana J, Ndungulile F, Massambu C: Evaluation of rapid HIV assays and development of national rapid HIV test algorithms in Dar es salaam, Tanzania. BMC Infect Dis 2009, 9:19. BioMed Central Full Text
• [25]Krown SE, Testa MA, Huang J: AIDS-related Kaposi’s sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification.AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997, 15:3085-3092.
• [26]Chalya PL, Gilyoma JM, Kanumba ES, Mawala B, Masalu N, Kahima JK, Rambau P: Dermatological malignancies at a University Teaching Hospital in northwestern Tanzania: a retrospective review of 154 cases. Tanzania J Health Res 2012, 1:3.
• [27]Sissolak G, Mayaud P: AIDS-related Kaposi’s sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa. Trop Med Int Health 2005, 10:981-992.
• [28]Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ: Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002, 94:1204-1210.
• [29]Ahmed A, Muktar HM: Epidemiology and treatment of Kaposi’s sarcoma in HIV-1 infected individuals in a poor resource setting. In Global View of HIV Infection. Edited by Venketaraman V. InTech, Croatia; 2011:103-126.
• [30]Onyango JF, Njiru A: Kaposi’s sarcoma in a Nairobi Hospital. East Afr Med J 2004, 81:120-123.
• [31]Mohammed AZ, Nwana EJC, Manasseh AN: Changing patterns of Kaposi sarcoma in Nigerians. Trop Doc 2005, 35:168-169.
• [32]Ahmed A, Isa MS, Garba HA, Kalayi GD, Muhammad I, Egler LJ: Influence of HIV infection on presentation of Kaposi’s sarcoma. Trop Doct 2001, 31:42-45.
• [33]Iregbu KC, Elegba OY: Prevalence of Kaposi’s sarcoma among adult HIV-seropositive patients seen in a designated HIV treatment and care center in Abuja, Nigeria. J Int Assoc Physicians AIDS Care (Chic) 2006, 5:115-118.
• [34]Mosam A, Hurkchand HP, Cassol E, Page T, Cassol S, Bodasing U, et al.: Characteristics of HIV-1-associated Kaposi’s sarcoma among women and men in South Africa. Int J STD AIDS 2008, 19:400-405.
• [35]Meditz AL, Borok M, MaWhinney S, Gudza I, Ndemera B, Gwanzura L, et al.: Gender differences in AIDS-associated Kaposi sarcoma in Harare, Zimbabwe. J Acquir Immune Defic Syndr 2007, 44:306-308.
• [36]Phipps W, Ssewankambo F, Nguyen H, Saracino M, Wald A, Corey L, et al.: Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda. PLoS One 2010, 5:e13936.
• [37]Asuquo ME, Ogunkeyede A, Bassey EE, Ebughe G: Kaposi sarcoma: changing trend in Calabar, southeastern Nigeria. Ann Afr Med 2008, 7:98-101.
• [38]Pitche PT, Kombate K, Owono F, Tchangai-Walla K: Kaposi’s sarcoma in a hospital setting in Lome (Togo): a study of 93 cases. Int J Dermatol 2007, 46:42-44.
• [39]Charles S, Siegfried J, Alex EC, et al.: Monoclonal origin of multicentric Kaposi’s sarcoma lesions. N Engl J Med 1997, 336:988-993.
• [40]Rabkin CS, Bedi G, Musabe E, et al.: AIDS related Kaposi’s sarcoma is a clonal neoplasm. Clin Cancer Res 1995, 1:257-260.
• [41]Lennette ET, BLackbourn DT, Levy JA: Antibodies to human herpes virus type 8 in the general population and in Kaposi’s sarcoma patients. Lancet 1996, 348:858-861.
• [42]Kedes DH, Operskalski E, Buseh M, et al.: The sero-epidemiology of herpes virus 8(Kaposi’s sarcoma associated Herpes virus) distribution of infection in Kaposi’s sarcoma risk group and evidence of sexual transmission. Nat Med 1996, 2:918-924.
• [43]Otu AA: Kaposi’s sarcoma: clinical, immunological and therapeutic consideration. Nigerian Med Pract 1990, 6:87-92.
• [44]Ashish U, Keith MS, Donald WN: Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma. Int J Nanomed 2007, 2:345-352.
• [45]Krown SE: Highly active antiretroviral therapy in AIDS-associated Kaposi’s sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi’s sarcoma. J Clin Oncol 2004, 22:399-402.
• [46]Feller L, Masipa JN, Wood NH, Raubenheimer EJ, Lemmer J: The prognostic significance of facial lymphoedema in HIV-seropositive subjects with Kaposi sarcoma. AIDS Res Therap 2008, 5:2. BioMed Central Full Text
• [47]Kibria R, Siraj U, Barde C: Kaposi’s sarcoma of the stomach and duodenum in human immunodeficiency virus infection. Dig Endosc 2010, 22:241-242.
• [48]Antman K, Chang Y: Kaposi’s sarcoma. N Engl J Med 2000, 342:1027-1038.
• [49]Zon LI, Groopman JE: Hematologic manifestations of the human immunodeficiency virus (HIV). Semin Hematol 1988, 25:208-218.
• [50]Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW: Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveilance project. Blood 1998, 91:301-308.
• [51]Moore RD, Keruly JC, Chaisson RE: Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:29-33.
• [52]Martellotta F, Berretta M, Vaccher E, Schioppa O, Zanet E, Tirelli U: AIDS-related Kaposi’s sarcoma: state of the art and therapeutic strategies. Curr HIV Res 2009, 7:634-638.
• [53]Koon HB, Fingleton B, Lee JY, et al.: Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr 2011, 56:64-68.
• [54]Makombe SD, Harries AD, Kwong-Leung YuJ, et al.: Outcomes of patients with Kaposi’s sarcoma who start antiretroviral therapy under routine programme conditions in Malawi. Trop Doct 2008, 38:5-7.
• [55]Nguyen HQ, Amalia SM, Kitahata MM, Rompaey SE, Wald A, Casper C: Persistent Kaposi sarcoma in the era of HAART: characterizing the predictors of clinical response. AIDS 2008, 22:937-945.
• [56]Tirelli U, Bernardi D: Impact of HAART on the clinical management of AIDS-related cancers. Euro J Cancer 2001, 37:1320-1324.
• [57]Guadalupe M, Pollock BH, Westbrook S, et al.: Risk factors influencing antibody responses to Kaposi’s sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy. J Acquir Immune Defic Syndr 2011, 56:83-90.